The Ministry of Health announced on Friday the launch of a new prevention strategy for the treatment of respiratory syncytial virus (RSV), with the inclusion of the monoclonal antibody nirsevimab (Beyfortus) in the state health system. This decision aims to reduce hospitalisations and serious complications from RSV, especially in infants and young children.